First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile Initial development ...
BioAge Labs is rated 'Hold' after a rally driven by BGE-102 Phase 1 data and Eli Lilly's Ventyx acquisition. Click to read my ...
BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback